Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma
Clinical and Experimental Medicine · 2024
DOI: 10.1007/s10238-024-01347-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Experimental Medicine, 2024. Verfasst von Punchita Rujirachaivej und 10 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Program in Clinical Pathology, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Multiple Myeloma, B-Cell Maturation Antigen, Receptors, Chimeric Antigen, Immunotherapy, Adoptive. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The National Research Council of Thailand (NRCT), The Office of National Higher Education Science Research and Innovation Policy Council (NXPO) through the Program Management Unit-Competitiveness (PMU-C), Mahidol University's Basic Research Fund (Fiscal Year 2022).
Abstract (Originalsprache)
Multiple myeloma (MM) is an incurable hematologic malignancy characterized by the rapid proliferation of malignant plasma cells within the bone marrow. Standard therapies often fail due to patient resistance. The US FDA has approved second-generation chimeric antigen receptor (CAR) T cells targeting B-cell maturation antigen (anti-BCMA-CAR2 T cells) for MM treatment. However, achieving enduring clinical responses remains a challenge in CAR T cell therapy. This study developed third-generation T cells with an anti-BCMA CAR (anti-BCMA-CAR3). The CAR incorporated a fully human scFv specific to BCMA, linked to the CD8 hinge region. The design included the CD28 transmembrane domain, two co-stimulatory domains (CD28 and 4-1BB), and the CD3ζ signaling domain (28BBζ). Lentiviral technology generated these modified T cells, which were compared against anti-BCMA-CAR2 T cells for efficacy against cancer. Anti-BCMA-CAR3 T cells exhibited significantly higher cytotoxic activity against BCMA-expressing cells (KMS-12-PE and NCI-H929) compared to anti-BCMA-CAR2 T cells. At an effector-to-target ratio of 10:1, anti-BCMA-CAR3 T cells induced lysis in 75.5 ± 3.8% of NCI-H929 cells, whereas anti-BCMA-CAR2 T cells achieved 56.7 ± 3.4% ( p = 0.0023). Notably, after twelve days of cultivation, anti-BCMA-CAR3 T cells nearly eradicated BCMA-positive cells (4.1 ± 2.1%), while anti-BCMA-CAR2 T cells allowed 36.8 ± 20.1% to survive. This study highlights the superior efficacy of anti-BCMA-CAR3 T cells against both low and high BCMA-expressing MM cells, surpassing anti-BCMA-CAR2 T cells. These findings suggest potential for advancing anti-BCMA-CAR3 T cells in chimeric antigen receptor T (CAR-T) therapy for relapsed/refractory MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate Program in Clinical Pathology, Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
- Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT) and Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand.
- Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
- Division of Transfusion Science, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand.
- Siriraj Center of Research Excellence for Cancer Immunotherapy (SiCORE-CIT) and Division of Molecular Medicine, Research Department, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, 10700, Thailand. mu…
Förderung
- The National Research Council of Thailand (NRCT)
- The Office of National Higher Education Science Research and Innovation Policy Council (NXPO) through the Program Management Unit-Competitiveness (PMU-C)
- Mahidol University's Basic Research Fund (Fiscal Year 2022)
- the Siriraj Research Fund of the Faculty of Medicine Siriraj Hospital, Mahidol University
- The National Science and Technology Development Agency (NSTDA) awarded a Royal Thai government scholarship
- Mahidol University
- Mahidol University Grants
- Siriraj Chalermphrakiat Grants
Zitieren
APA
Rujirachaivej, P., Siriboonpiputtana, T., Luangwattananun, P., Yuti, P., Wutti-In, Y., Choomee, K., Sujjitjoon, J., Chareonsirisuthigul, T., Rerkamnuaychoke, B., Junking, M., & Yenchitsomanus, P. T. (2024). Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma. Clinical and Experimental Medicine. https://doi.org/10.1007/s10238-024-01347-7
Vancouver
Rujirachaivej P, Siriboonpiputtana T, Luangwattananun P, Yuti P, Wutti-In Y, Choomee K, et al. Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma. Clinical and Experimental Medicine. 2024. doi:10.1007/s10238-024-01347-7
BibTeX
@article{Rujirachaivej2024,
author = {Rujirachaivej, Punchita and Siriboonpiputtana, Teerapong and Luangwattananun, Piriya and Yuti, Pornpimon and Wutti-In, Yupanun and Choomee, Kornkan and Sujjitjoon, Jatuporn and Chareonsirisuthigul, Takol and Rerkamnuaychoke, Budsaba and Junking, Mutita and Yenchitsomanus, Pa-Thai},
title = {Therapeutic potential of third-generation chimeric antigen receptor T cells targeting B cell maturation antigen for treating multiple myeloma},
journal = {Clinical and Experimental Medicine},
year = {2024},
doi = {10.1007/s10238-024-01347-7}
}
EUVIMED